Filing Details
- Accession Number:
- 0000925421-17-000361
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-25 17:25:03
- Reporting Period:
- 2017-09-22
- Accepted Time:
- 2017-09-25 17:25:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1711279 | Krystal Biotech Inc. | KRYS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1298711 | Suma Krishnan | C/O Krystal Biotech, Inc. 2100 Wharton Street, Suite 701 Pittsburgh PA 15203 | Chief Operating Officer | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-09-22 | 100,000 | $10.00 | 1,935,249 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-09-22 | 112,162 | $0.00 | 112,162 | No | 4 | C | Indirect | By trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | C | Indirect | By trust |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2017-09-22 | 112,162 | $0.00 | 112,162 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,935,249 | Indirect | By spouse |
Footnotes
- The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.
- Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
- Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person.
Billionaire Hedge Funds
